Search

Displaying results 9341 - 9350 of 10000 in total
  1. Drug

    XL784

    go.drugbank.com/drugs/DB04991
    Investigational

    XL784 was specifically optimized to be MMP-1 sparing, thus potentially enhancing its safety profile and enabling higher dosing compared with other previously studied metalloprotease inhibitors. … XL784 is a potent inhibitor of the ADAM-10 metalloprotease enzyme, a target of significant interest because of its important role in blood vessel formation and cell proliferation.

  2. Drug

    Satraplatin

    go.drugbank.com/drugs/DB04996
    Investigational

    Satraplatin is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy.

  3. Drug

    ATL1102

    go.drugbank.com/drugs/DB04997
    Investigational

    ATL1102 is a second-generation antisense inhibitor of CD49d, an immunesystem protein known as VLA-4, an immune cell molecule. It works by entering cells and targeting genes.

  4. Drug

    MBO7133

    go.drugbank.com/drugs/DB04999
    Experimental

    MB07133 uses our HepDirect technology to target a prodrug form of araCMP specifically to the liver. … MB07133 is a HepDirect prodrug of an activated form of cytarabine (araC), an anti-cancer drug that is used to treat leukemia but is ineffective against primary liver cancer.

  5. Drug

    Apadenoson

    go.drugbank.com/drugs/DB05009
    Investigational

    Apadenoson is a selective A2a adenosine receptor agonist designed for use as a pharmacologic stress agent in cardiac perfusion imaging studies.

    Categories: Adenosine A receptor agonists, Heterocyclic Compounds, 2-Ring
  6. Drug

    XEN-2174

    go.drugbank.com/drugs/DB05012
    Experimental

    XEN-2174 is a synthetic drug modeled on a peptide from the venom of a cone shell found on Australia's Great Barrier Reef. … XEN-2174 represents a new class of molecules, called the chi conopeptides that selectively inhibit the Norepinephrine Transporter (NET).

  7. Drug

    YSIL6

    go.drugbank.com/drugs/DB05017
    Experimental

    The molecule works by inhibiting TNF-alpha and IL-6 production in T-cells and macrophages, and by inhibiting T-cell proliferation and migration. … YSIL6 is a small-molecule drug in development for the treatment of inflammatory diseases, including rheumatoid arthritis and psoriasis.

  8. Drug

    EMZ702

    go.drugbank.com/drugs/DB05021
    Investigational

    compared to interferon and ribavirin alone. … EMZ702, a non-toxic agent that has strong anti-viral synergy with interferon, is an ideal candidate for combination with current standard hepatitis C treatments.

  9. Drug

    Arimoclomol

    go.drugbank.com/drugs/DB05025
    Approved

    Arimoclomol is a hydroxylamine derivative [A264414] and a heat-shock protein-70 (HSP70) co-inducer. … [L51384] Arimoclomol was approved by the FDA on September 20, 2024, making it the first treatment for Niemann-Pick disease, type C (NPC).

    Synonyms: 3-PYRIDINECARBOXIMIDOYL CHLORIDE, N-((2R)-2-HYDROXY-3-(1-PIPERIDINYL)PROPOXY), 1-OXIDE, N-[(2R)-2-Hydroxy-3-(1-piperidyl)propoxy]pyridine-3-carboximidoyl chloride, 1-oxideCategories: MATE 1 Substrates, MATE 2 Substrates
  10. Drug

    DG041

    go.drugbank.com/drugs/DB05027
    Experimental

    EP3 is a target that associates with increased risk of various vascular diseases. … DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor for prostaglandins E2.